Avanos Medical (AVNS) Stock Forecast, Price Target & Predictions
AVNS Stock Forecast
Avanos Medical stock forecast is as follows: an average price target of $23.00 (represents a 23.13% upside from AVNS’s last price of $18.68) and a rating consensus of 'Hold', based on 2 wall street analysts offering a 1-year stock forecast.
AVNS Price Target
The average price target for Avanos Medical (AVNS) is $23.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $26.00 to $20.00. This represents a potential 23.13% upside from AVNS's last price of $18.68.
AVNS Analyst Ratings
According to 2 Wall Street analysts, Avanos Medical's rating consensus is 'Hold'. The analyst rating breakdown for AVNS stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 1 'Hold' (50.00%), 1 'Sell' (50.00%), and 0 'Strong Sell' (0.00%).
Avanos Medical Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 30, 2024 | Rick Wise | Stifel Nicolaus | $20.00 | $18.58 | 7.64% | 7.07% |
| Jan 06, 2023 | - | Morgan Stanley | $26.00 | $26.99 | -3.67% | 39.19% |
| Jul 18, 2022 | - | Stifel Nicolaus | $28.00 | $26.89 | 4.13% | 49.89% |
| Jul 15, 2022 | - | Morgan Stanley | $28.00 | $27.19 | 2.98% | 49.89% |
| May 05, 2022 | - | Morgan Stanley | $33.00 | $29.29 | 12.67% | 76.66% |
The latest Avanos Medical stock forecast, released on Oct 30, 2024 by Rick Wise from Stifel Nicolaus, set a price target of $20.00, which represents a 7.64% increase from the stock price at the time of the forecast ($18.58), and a 7.07% increase from AVNS last price ($18.68).
Avanos Medical Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 1 |
| Avg Price Target | $20.00 | $20.00 | $20.00 |
| Last Closing Price | $18.68 | $18.68 | $18.68 |
| Upside/Downside | 7.07% | 7.07% | 7.07% |
In the current month, the average price target of Avanos Medical stock is $20.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 7.07% increase as opposed to Avanos Medical's last price of $18.68. This month's average price target is down 0.00% compared to last quarter, and down 0.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jan 06, 2023 | Morgan Stanley | Underweight | Underweight | Hold |
| Jul 15, 2022 | Morgan Stanley | Underweight | Underweight | Hold |
| Apr 26, 2022 | Zacks Investment Research | - | Hold | Downgrade |
Avanos Medical's last stock rating was published by Morgan Stanley on Jan 06, 2023. The company gave AVNS a "Underweight" rating, the same as its previous rate.
Avanos Medical Financial Forecast
Avanos Medical Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $171.30M | $169.40M | $191.70M | $217.50M | $202.10M | $203.00M | $197.40M | $193.40M | $184.10M | $186.40M | $180.70M | $185.00M | $185.70M | $163.70M | $180.40M | $189.80M | $171.40M | $172.20M | $164.20M | $156.40M | $395.60M |
| Avg Forecast | $184.33M | $177.63M | $178.33M | $172.60M | $177.23M | $175.33M | $170.67M | $162.90M | $170.43M | $169.60M | $186.30M | $195.20M | $217.30M | $205.47M | $208.28M | $197.80M | $191.32M | $185.02M | $180.56M | $175.68M | $184.15M | $165.87M | $147.90M | $175.77M | $178.58M | $179.98M | $172.02M | $163.72M | $344.08M | $346.15M |
| High Forecast | $185.79M | $179.03M | $179.74M | $173.23M | $180.34M | $175.40M | $170.67M | $164.18M | $174.84M | $170.00M | $187.77M | $196.74M | $219.01M | $205.47M | $208.28M | $197.80M | $191.32M | $185.02M | $180.56M | $175.68M | $184.15M | $165.87M | $147.90M | $175.77M | $178.58M | $179.98M | $172.02M | $163.72M | $412.90M | $415.38M |
| Low Forecast | $183.20M | $176.54M | $177.24M | $171.33M | $175.33M | $175.27M | $170.67M | $161.90M | $167.59M | $168.80M | $185.15M | $194.00M | $215.96M | $205.47M | $208.28M | $197.80M | $191.32M | $185.02M | $180.56M | $175.68M | $184.15M | $165.87M | $147.90M | $175.77M | $178.58M | $179.98M | $172.02M | $163.72M | $275.26M | $276.92M |
| # Analysts | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 19 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.01% | 0.91% | 0.98% | 1.00% | 0.98% | 0.97% | 1.00% | 1.01% | 1.00% | 1.03% | 1.03% | 1.00% | 1.12% | 1.11% | 1.03% | 1.06% | 0.95% | 1.00% | 1.00% | 0.45% | 1.14% |
Avanos Medical's average Quarter revenue forecast for Dec 23 based on 3 analysts is $170.43M, with a low forecast of $167.59M, and a high forecast of $174.84M. AVNS's average Quarter revenue forecast represents a -0.51% decrease compared to the company's last Quarter revenue of $171.30M (Sep 23).
Avanos Medical EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 19 |
| EBITDA | - | - | - | - | - | - | - | - | - | $13.10M | $9.90M | $15.20M | $40.30M | $30.60M | $30.80M | $20.30M | $34.50M | $13.40M | $2.20M | $-2.70M | $-33.90M | $10.80M | $9.20M | $11.90M | $9.10M | $-8.10M | $700.00K | $-13.80M | $33.30M | $42.90M |
| Avg Forecast | $6.11M | $5.89M | $5.91M | $5.72M | $5.87M | $5.81M | $5.66M | $24.56M | $5.65M | $5.62M | $6.17M | $22.33M | $32.26M | $13.96M | $14.15M | $20.30M | $13.00M | $12.57M | $12.27M | $-2.13M | $12.51M | $11.27M | $10.05M | $11.90M | $12.13M | $12.23M | $11.69M | $-11.68M | $73.56M | $36.77M |
| High Forecast | $6.16M | $5.93M | $5.96M | $5.74M | $5.98M | $5.81M | $5.66M | $29.48M | $5.79M | $5.63M | $6.22M | $26.80M | $38.71M | $13.96M | $14.15M | $24.36M | $13.00M | $12.57M | $12.27M | $-1.71M | $12.51M | $11.27M | $10.05M | $14.28M | $12.13M | $12.23M | $11.69M | $-9.34M | $88.28M | $44.13M |
| Low Forecast | $6.07M | $5.85M | $5.87M | $5.68M | $5.81M | $5.81M | $5.66M | $19.65M | $5.55M | $5.59M | $6.14M | $17.86M | $25.81M | $13.96M | $14.15M | $16.24M | $13.00M | $12.57M | $12.27M | $-2.56M | $12.51M | $11.27M | $10.05M | $9.52M | $12.13M | $12.23M | $11.69M | $-14.01M | $58.85M | $29.42M |
| Surprise % | - | - | - | - | - | - | - | - | - | 2.33% | 1.60% | 0.68% | 1.25% | 2.19% | 2.18% | 1.00% | 2.65% | 1.07% | 0.18% | 1.27% | -2.71% | 0.96% | 0.92% | 1.00% | 0.75% | -0.66% | 0.06% | 1.18% | 0.45% | 1.17% |
3 analysts predict AVNS's average Quarter EBITDA for Dec 23 to be $5.65M, with a high of $5.79M and a low of $5.55M. This is -56.88% lower than Avanos Medical's previous annual EBITDA (Sep 23) of $13.10M.
Avanos Medical Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 19 |
| Net Income | - | - | - | - | - | - | - | - | - | $-3.70M | $-68.10M | $-500.00K | $16.90M | $15.70M | $11.40M | $5.80M | $10.00M | $-35.10M | $37.90M | $-7.60M | $-47.20M | $19.30M | $-3.00M | $3.70M | $-6.10M | $-11.50M | $-8.00M | $-20.30M | $20.20M | $12.80M |
| Avg Forecast | $23.14M | $20.35M | $18.95M | $15.07M | $18.48M | $16.47M | $13.36M | $7.02M | $17.09M | $13.05M | $13.86M | $6.38M | $9.35M | $16.32M | $17.69M | $5.80M | $18.61M | $13.50M | $10.80M | $-6.00M | $10.09M | $4.63M | $-4.63M | $3.70M | $14.64M | $14.47M | $11.69M | $-17.18M | $44.62M | $10.97M |
| High Forecast | $23.38M | $20.56M | $19.15M | $16.11M | $20.69M | $16.47M | $13.37M | $8.42M | $18.01M | $13.98M | $14.01M | $7.66M | $11.22M | $16.32M | $17.69M | $6.96M | $18.61M | $13.50M | $10.80M | $-4.80M | $10.09M | $4.63M | $-4.63M | $4.44M | $14.64M | $14.47M | $11.69M | $-13.74M | $53.55M | $13.17M |
| Low Forecast | $22.96M | $20.19M | $18.80M | $14.55M | $17.16M | $16.46M | $13.35M | $5.61M | $16.63M | $12.12M | $13.75M | $5.10M | $7.48M | $16.32M | $17.69M | $4.64M | $18.61M | $13.50M | $10.80M | $-7.20M | $10.09M | $4.63M | $-4.63M | $2.96M | $14.64M | $14.47M | $11.69M | $-20.61M | $35.70M | $8.78M |
| Surprise % | - | - | - | - | - | - | - | - | - | -0.28% | -4.91% | -0.08% | 1.81% | 0.96% | 0.64% | 1.00% | 0.54% | -2.60% | 3.51% | 1.27% | -4.68% | 4.17% | 0.65% | 1.00% | -0.42% | -0.79% | -0.68% | 1.18% | 0.45% | 1.17% |
Avanos Medical's average Quarter net income forecast for Mar 23 is $6.38M, with a range of $5.10M to $7.66M. AVNS's average Quarter net income forecast represents a -62.25% decrease compared to the company's last Quarter net income of $16.90M (Dec 22).
Avanos Medical SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 19 |
| SG&A | - | - | - | - | - | - | - | - | - | $78.70M | $93.00M | $92.70M | $82.60M | $82.10M | $87.10M | $90.10M | $75.20M | $75.00M | $76.70M | $73.40M | $82.20M | $82.40M | $76.90M | $91.10M | $103.60M | $94.40M | $94.70M | $106.40M | $86.40M | $101.20M |
| Avg Forecast | $85.90M | $82.78M | $83.11M | $80.44M | $82.59M | $81.71M | $79.53M | $109.02M | $79.43M | $79.04M | $86.82M | $99.11M | $70.31M | $94.84M | $96.13M | $90.10M | $88.31M | $85.40M | $83.34M | $57.95M | $85.00M | $76.56M | $68.27M | $91.10M | $82.43M | $83.07M | $79.40M | $90.03M | $190.87M | $86.74M |
| High Forecast | $86.58M | $83.43M | $83.76M | $80.73M | $84.04M | $81.74M | $79.53M | $130.83M | $81.48M | $79.22M | $87.50M | $118.93M | $84.37M | $94.84M | $96.13M | $108.12M | $88.31M | $85.40M | $83.34M | $69.54M | $85.00M | $76.56M | $68.27M | $109.32M | $82.43M | $83.07M | $79.40M | $108.04M | $229.04M | $104.09M |
| Low Forecast | $85.37M | $82.27M | $82.60M | $79.85M | $81.71M | $81.68M | $79.53M | $87.22M | $78.10M | $78.66M | $86.29M | $79.29M | $56.25M | $94.84M | $96.13M | $72.08M | $88.31M | $85.40M | $83.34M | $46.36M | $85.00M | $76.56M | $68.27M | $72.88M | $82.43M | $83.07M | $79.40M | $72.02M | $152.69M | $69.39M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.00% | 1.07% | 0.94% | 1.17% | 0.87% | 0.91% | 1.00% | 0.85% | 0.88% | 0.92% | 1.27% | 0.97% | 1.08% | 1.13% | 1.00% | 1.26% | 1.14% | 1.19% | 1.18% | 0.45% | 1.17% |
Avanos Medical's average Quarter SG&A projection for Dec 23 is $79.43M, based on 3 Wall Street analysts, with a range of $78.10M to $81.48M. The forecast indicates a 0.92% rise compared to AVNS last annual SG&A of $78.70M (Sep 23).
Avanos Medical EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 19 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.08 | $-1.46 | $-0.01 | $0.36 | $0.34 | $0.24 | $0.12 | $0.21 | $-0.73 | $0.79 | $-0.16 | $-0.99 | $0.40 | $-0.06 | $0.08 | $-0.13 | $-0.24 | $-0.17 | $-0.43 | $0.43 | $0.27 |
| Avg Forecast | $0.50 | $0.44 | $0.41 | $0.32 | $0.40 | $0.35 | $0.29 | $0.21 | $0.37 | $0.28 | $0.30 | $0.28 | $0.49 | $0.35 | $0.38 | $0.26 | $0.40 | $0.29 | $0.23 | $0.18 | $0.22 | $0.10 | $-0.10 | $0.16 | $0.32 | $0.31 | $0.25 | $0.13 | $0.49 | $0.36 |
| High Forecast | $0.50 | $0.44 | $0.41 | $0.35 | $0.44 | $0.35 | $0.29 | $0.21 | $0.39 | $0.30 | $0.30 | $0.28 | $0.50 | $0.35 | $0.38 | $0.26 | $0.40 | $0.29 | $0.23 | $0.18 | $0.22 | $0.10 | $-0.10 | $0.16 | $0.32 | $0.31 | $0.25 | $0.13 | $0.58 | $0.43 |
| Low Forecast | $0.49 | $0.43 | $0.40 | $0.31 | $0.37 | $0.35 | $0.29 | $0.21 | $0.36 | $0.26 | $0.30 | $0.27 | $0.49 | $0.35 | $0.38 | $0.26 | $0.40 | $0.29 | $0.23 | $0.18 | $0.22 | $0.10 | $-0.10 | $0.16 | $0.32 | $0.31 | $0.25 | $0.13 | $0.39 | $0.29 |
| Surprise % | - | - | - | - | - | - | - | - | - | -0.28% | -4.91% | -0.04% | 0.73% | 0.96% | 0.63% | 0.46% | 0.52% | -2.50% | 3.39% | -0.90% | -4.54% | 4.00% | 0.60% | 0.50% | -0.41% | -0.77% | -0.67% | -3.25% | 0.88% | 0.75% |
According to 1 Wall Street analysts, Avanos Medical's projected average Quarter EPS for Mar 23 is $0.28, with a low estimate of $0.27 and a high estimate of $0.28. This represents a -23.61% decrease compared to AVNS previous annual EPS of $0.36 (Dec 22).
Avanos Medical Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| NVRO | Nevro | $4.52 | $32.72 | 623.89% | Hold |
| SGHT | Sight Sciences | $3.80 | $9.00 | 136.84% | Hold |
| ESTA | Establishment Labs | $37.79 | $78.00 | 106.40% | Buy |
| KIDS | OrthoPediatrics | $22.93 | $39.60 | 72.70% | Buy |
| LIVN | LivaNova | $52.10 | $70.50 | 35.32% | Buy |
| CNMD | CONMED | $72.24 | $96.00 | 32.89% | Buy |
| OFIX | Orthofix Medical | $18.08 | $24.00 | 32.74% | - |
| AVNS | Avanos Medical | $18.68 | $23.00 | 23.13% | Hold |
| FNA | Paragon 28 | $10.01 | $11.50 | 14.89% | Buy |
| AORT | Artivion | $26.65 | $30.60 | 14.82% | Buy |
| ITGR | Integer | $133.18 | $138.00 | 3.62% | Buy |
| SRDX | Surmodics | $38.72 | $39.50 | 2.01% | Buy |
| GKOS | Glaukos | $138.44 | $123.44 | -10.84% | Buy |